An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

NCT03580564 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: KL-A167

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.